ArticleNature2022
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Open access · hybridAbstract readPublished Erratum
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 29 citations in OpenAlex.
- FGFR2-triggered autophagy and activation of Nrf-2 reduce breast cancer cell response to anti-ER drugs.Cellular & molecular biology letters · 2024Article
Corrections and comments
- Erratum for
Authors and funding
48 authors at 11 institutions in 3 countries.
Daniel Zingg *Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-6450-2534
Jinhyuk Bhin *Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-8898-4531
Julia Yemelyanenko *Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-9697-2039
Sjors M Kas *Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Frank RolfsDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Catrin LutzDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Jessica K LeeFoundation Medicine, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-4333-5092
Sjoerd KlarenbeekExperimental Animal Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-1891-1940
Ian M SilvermanIncyte Research Institute, Wilmington, DE, USA.ORCID http://orcid.org/0000-0003-3819-6726
Stefano AnnunziatoDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Chang S ChanDepartment of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.ORCID http://orcid.org/0000-0001-9897-4759
Sander R PiersmaOncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Timo EijkmanDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Madelon BadouxDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ewa GogolaDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Bjørn SiteurMouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Justin SprengersMouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Bim de KleinDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Richard R de Goeij-de HaasOncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Gregory M RiedlingerDepartment of Medicine and Pharmacology, Rutgers University, Piscataway, NJ, USA.
Hua KeDepartment of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Russell MadisonFoundation Medicine, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7838-2526
Anne Paulien DrenthDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Eline van der BurgDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Eva SchutDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Linda HennemanDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Martine H van MiltenburgDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Natalie ProostMouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Huiling ZhenIncyte, Wilmington, DE, USA.
Ellen WientjensDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Roebi de BruijnDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Julian R de RuiterDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Ute BoonDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Renske de Korte-GrimmerinkMouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Bastiaan van GerwenMouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Luis FélizIncyte Biosciences International, Morges, Switzerland.ORCID http://orcid.org/0000-0003-0659-229X
Ghassan K Abou-AlfaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jeffrey S RossFoundation Medicine, Cambridge, MA, USA.
Marieke van de VenMouse Clinic for Cancer and Aging, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Sven RottenbergDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-2044-9844
Edwin CuppenOncode Institute, Utrecht, The Netherlands.
Anne Vaslin ChessexDebiopharm International, Lausanne, Switzerland.
Siraj M AliFoundation Medicine, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-7477-4023
Timothy C BurnIncyte Research Institute, Wilmington, DE, USA.ORCID http://orcid.org/0000-0001-6648-4333
Connie R JimenezOncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Shridar GanesanDepartment of Medicine, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. ganesash@cinj.rutgers.edu.
Lodewyk F A WesselsOncode Institute, Utrecht, The Netherlands. l.wessels@nki.nl.ORCID http://orcid.org/0000-0002-1656-6995
Jos JonkersDivision of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands. j.jonkers@nki.nl.ORCID http://orcid.org/0000-0002-9264-9792
The Netherlands Cancer Institute · NLRutgers, The State University of New Jersey · USAmsterdam University Medical Centers · NLFoundation Medicine (United States)Incyte (United States) · USDebiopharm (Switzerland) · CHMemorial Sloan Kettering Cancer Center · USOncode Institute · NLSUNY Upstate Medical University · USUniversity Medical Center Utrecht · NLUniversity of Bern · CH
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.